vs
Side-by-side financial comparison of Cherry Hill Mortgage Investment Corp (CHMI) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Cherry Hill Mortgage Investment Corp is the larger business by last-quarter revenue ($11.8M vs $9.1M, roughly 1.3× Protalix BioTherapeutics, Inc.). On growth, Cherry Hill Mortgage Investment Corp posted the faster year-over-year revenue change (-37.2% vs -49.9%). Over the past eight quarters, Protalix BioTherapeutics, Inc.'s revenue compounded faster (-6.7% CAGR vs -15.2%).
Cherry Hill Mortgage Investment Corp is a U.S.-headquartered real estate finance firm focused on acquiring, investing in and managing residential mortgage-related assets. Its core holdings include agency mortgage-backed securities, residential loans and mortgage servicing rights, operating primarily in the U.S. domestic housing finance market.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
CHMI vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.8M | $9.1M |
| Net Profit | — | $-5.5M |
| Gross Margin | 78.9% | 49.4% |
| Operating Margin | 72.1% | -51.1% |
| Net Margin | — | -60.3% |
| Revenue YoY | -37.2% | -49.9% |
| Net Profit YoY | — | -184.8% |
| EPS (diluted) | $0.18 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.8M | $9.1M | ||
| Q3 25 | $8.6M | $17.9M | ||
| Q2 25 | $6.0M | $15.7M | ||
| Q1 25 | $-3.0M | $10.1M | ||
| Q4 24 | $18.7M | $18.2M | ||
| Q3 24 | $-7.1M | $18.0M | ||
| Q2 24 | $6.6M | $13.5M | ||
| Q1 24 | $16.3M | — |
| Q4 25 | — | $-5.5M | ||
| Q3 25 | $4.5M | $2.4M | ||
| Q2 25 | $1.6M | $164.0K | ||
| Q1 25 | $-7.0M | $-3.6M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | $-12.4M | $3.2M | ||
| Q2 24 | $784.0K | $-2.2M | ||
| Q1 24 | $12.1M | — |
| Q4 25 | 78.9% | 49.4% | ||
| Q3 25 | 73.2% | 53.4% | ||
| Q2 25 | 67.7% | 62.5% | ||
| Q1 25 | 183.4% | 19.1% | ||
| Q4 24 | 83.3% | 78.7% | ||
| Q3 24 | 145.3% | 53.4% | ||
| Q2 24 | 47.5% | 29.8% | ||
| Q1 24 | 83.9% | — |
| Q4 25 | 72.1% | -51.1% | ||
| Q3 25 | 56.0% | 11.9% | ||
| Q2 25 | 44.4% | 7.5% | ||
| Q1 25 | 223.6% | -41.0% | ||
| Q4 24 | 76.2% | 39.6% | ||
| Q3 24 | 171.8% | 22.2% | ||
| Q2 24 | 22.0% | -18.0% | ||
| Q1 24 | 78.0% | — |
| Q4 25 | — | -60.3% | ||
| Q3 25 | 52.7% | 13.2% | ||
| Q2 25 | 25.9% | 1.0% | ||
| Q1 25 | 229.2% | -35.8% | ||
| Q4 24 | — | 35.6% | ||
| Q3 24 | 175.8% | 18.0% | ||
| Q2 24 | 11.9% | -16.4% | ||
| Q1 24 | 73.7% | — |
| Q4 25 | $0.18 | $-0.06 | ||
| Q3 25 | $0.05 | $0.03 | ||
| Q2 25 | $-0.03 | $0.00 | ||
| Q1 25 | $-0.29 | $-0.05 | ||
| Q4 24 | $0.30 | $0.10 | ||
| Q3 24 | $-0.49 | $0.03 | ||
| Q2 24 | $-0.06 | $-0.03 | ||
| Q1 24 | $0.32 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $54.9M | $14.7M |
| Total DebtLower is stronger | $146.3M | — |
| Stockholders' EquityBook value | $236.0M | $48.2M |
| Total Assets | $1.5B | $82.3M |
| Debt / EquityLower = less leverage | 0.62× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $54.9M | $14.7M | ||
| Q3 25 | $55.4M | $13.6M | ||
| Q2 25 | $58.0M | $17.9M | ||
| Q1 25 | $47.3M | $19.5M | ||
| Q4 24 | $46.3M | $19.8M | ||
| Q3 24 | $50.2M | $27.4M | ||
| Q2 24 | $52.4M | $23.4M | ||
| Q1 24 | $47.5M | — |
| Q4 25 | $146.3M | — | ||
| Q3 25 | $148.0M | — | ||
| Q2 25 | $150.1M | — | ||
| Q1 25 | $150.1M | — | ||
| Q4 24 | $152.1M | — | ||
| Q3 24 | $151.8M | — | ||
| Q2 24 | $160.5M | — | ||
| Q1 24 | $167.5M | — |
| Q4 25 | $236.0M | $48.2M | ||
| Q3 25 | $233.1M | $52.9M | ||
| Q2 25 | $229.9M | $49.9M | ||
| Q1 25 | $226.6M | $45.2M | ||
| Q4 24 | $230.3M | $43.2M | ||
| Q3 24 | $236.7M | $32.4M | ||
| Q2 24 | $234.5M | $28.6M | ||
| Q1 24 | $247.0M | — |
| Q4 25 | $1.5B | $82.3M | ||
| Q3 25 | $1.5B | $82.3M | ||
| Q2 25 | $1.5B | $78.5M | ||
| Q1 25 | $1.4B | $73.9M | ||
| Q4 24 | $1.5B | $73.4M | ||
| Q3 24 | $1.6B | $61.6M | ||
| Q2 24 | $1.4B | $91.5M | ||
| Q1 24 | $1.4B | — |
| Q4 25 | 0.62× | — | ||
| Q3 25 | 0.63× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.66× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.68× | — | ||
| Q1 24 | 0.68× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.1M | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.1M | $2.0M | ||
| Q3 25 | $-2.4M | $-3.7M | ||
| Q2 25 | $12.5M | $-5.2M | ||
| Q1 25 | $682.0K | $-5.1M | ||
| Q4 24 | $-4.7M | $4.0M | ||
| Q3 24 | $4.4M | $4.1M | ||
| Q2 24 | $4.1M | $-3.6M | ||
| Q1 24 | $-19.1M | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -0.53× | -1.58× | ||
| Q2 25 | 7.98× | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | 5.18× | — | ||
| Q1 24 | -1.58× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHMI
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
